Skip to main content

Table 3 Satisfaction with medication using the SATMED-Q subscales at 6 and 12 months and PEMAT-A/V scores at 2 months and 4 months post-intervention

From: SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout

  Gout storytelling
N = 152
Control
N = 154
Difference (95% CI) p value
  Estimate (95% CI) Estimate (95% CI)   
SATMED-Q subscales; 6 months
 Total score (0–100) 63.74 (59.01; 68.47) 66.28 (61.58; 70.98) −2.54 (−9.21; 4.12) 0.45
 Undesirable side effects (0–100) 9.26 (8.55; 9.97) 9.56 (8.86; 10.27) −0.30 (−1.30; 0.70) 0.55
 Treatment effectiveness (0–100) 4.55 (4.03; 5.08) 4.58 (4.06; 5.10) −0.025 (−0.77; 0.72) 0.95
 Convenience of use (0–100) 7.59 (6.86; 8.31) 8.62 (7.89; 9.34) −1.03 (−2.06; 0.00) 0.05
 Impact on daily living/activities (0–100) 7.57 (6.88; 8.27) 7.83 (7.14; 8.52) −0.26 (−1.24; 0.72) 0.60
 Medical care (0–100) 5.28 (4.78; 5.78) 5.31 (4.81; 5.80) −0.03 (−0.73; 0.68) 0.94
 Global satisfaction (0–100) 9.09 (8.42; 9.77) 9.18 (8.50; 9.85) −0.08 (−1.04; 0.87) 0.86
SATMED-Q subscales: 12 months
 Total score (0–100) 62.16 (57.09; 67.23) 67.43 (62.39; 72.47) −5.27 (−12.42; 1.88) 0.15
 Undesirable side effects (0–100) 8.95 (8.22; 9.68) 9.77 (9.05; 10.50) −0.83 (−1.86; 0.21) 0.12
 Treatment effectiveness (0–100) 4.41 (3.91; 4.91) 5.12 (4.62; 5.61) −0.71 (−1.41; 0.00) 0.05
 Convenience of use (0–100) 7.71 (6.99; 8.43) 8.39 (7.67; 9.11) −0.68 (−1.70; 0.34) 0.19
 Impact on daily living/activities (0–100) 7.62 (6.92; 8.33) 8.08 (7.38; 8.79) −0.46 (−1.45; 0.54) 0.37
 Medical care (0–100) 4.96 (4.45; 5.47) 5.25 (4.75; 5.76) −0.29 (−1.01; 0.43) 0.43
 Global satisfaction (0–100) 8.62 (7.92; 9.31) 9.23 (8.54; 9.92) −0.62 (−1.60; 0.37) 0.22
  N (%) N (%) Difference (95% CI) p value
SATMED-Q side effect—yes     
 6 months 9 (7.2%) 10 (7.4%) 0.97 (0.38; 2.47) 0.95
 12 months 9 (7.6%) 5 (3.8%) 2.06 (0.67; 6.34) 0.21
PEMAT-A/V total Estimate (95% CI) Estimate (95% CI) Difference (95% CI)  
 Baseline 66.80 (64.85; 68.76) 65.61 (63.67; 67.55) 1.19 (−1.56; 3.95) 0.40
 2 months 76.23 (71.19; 81.28) 68.48 (63.47; 73.49) 7.75 (0.65; 14.86) 0.03
 4 months 64.64 (58.37; 70.91) 58.96 (52.72; 65.19) 5.68 (−3.16; 14.53) 0.21
PEMAT-A/V understandable subscale score     
 Baseline 92.16 (89.90; 94.41) 91.26 (89.02; 93.50) 0.90 (−2.28; 4.07) 0.58
 2 months 84.16 (78.61; 89.71) 76.22 (70.71; 81.74) 7.94 (0.11; 15.76) 0.05
 4 months 71.66 (64.74; 78.58) 65.73 (58.86; 72.61) 5.93 (−3.83; 15.69) 0.24
PEMAT-A/V actionable subscale score     
 Baseline 91.12 (88.10; 94.13) 88.64 (85.64; 91.63) 2.48 (−1.77; 6.73) 0.25
 2 months 83.72 (78.06; 89.37) 75.16 (69.54; 80.78) 8.55 (0.58; 16.53) 0.04
 4 months 69.57 (62.65; 76.49) 64.45 (57.57; 71.32) 5.12 (−4.63; 14.88) 0.30
  1. The SATMED-Q contains 17 items, each scored on a 5-point Likert scale. The total composite score ranges between 0 and 68. The score was converted to a percentage as recommended by the author of the original version (=(raw score*100)/68); higher score = more satisfaction with medication
  2. SATMED-Q, Satisfaction with Medications Questionnaire; PEMAT-A/V, Patient Education Materials Assessment Tool for Audiovisual Materials